This database contains 750 studies, archived under the term: "aged, 80 and over"
Click here to filter this large number of results.
Effects of dementia-care mapping on residents and staff of care homes: a pragmatic cluster-randomised controlled trial
van de Ven, Geertje,
Draskovic, Irena,
Adang, Eddy M. M.,
Donders, Rogier,
Zuidema, Sytse U.,
Koopmans, Raymond T. C. M.,
Vernooij-Dassen, Myrra J. F. J.
Background: The effectiveness of dementia-care mapping (DCM) for institutionalised people with dementia has been demonstrated in an explanatory cluster-randomised controlled trial (cRCT) with two DCM researchers carrying out the DCM intervention. In order to be able to inform daily practice, we studied DCM effectiveness in a pragmatic cRCT involving a wide range of care homes […]
Effects of SolCos model-based individual reminiscence on older adults with mild to moderate dementia due to Alzheimer disease: a pilot study
Van Bogaert, Peter,
Van Grinsven, Regine,
Tolson, Debbie,
Wouters, Kristien,
Engelborghs, Sebastiaan,
Van der Mussele, Stefan
Objective: To examine effects of individual thematically-based reminiscence sessions based on the SolCos model for older adults with dementia because of Alzheimer disease (AD) as a pilot study.; Background: Reminiscence activities are popular within nursing homes and generally considered to be enjoyable and helpful, however, there is a paucity of robust data demonstrating therapeutic impact. […]
Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
Unterberger, Ursula,
Lachmann, Ingolf,
Voigtländer, Till,
Pirker, Walter,
Berghoff, Anna S.,
Flach, Katharina,
Wagner, Uta,
Geneste, Aline,
Perret-Liaudet, Armand,
Kovacs, Gabor G.
With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of […]
Prevalence of anosognosia in Alzheimer’s disease
Turró-Garriga, Oriol,
Conde-Sala, Josep Lluís,
Reñé-Ramírez, Ramón,
López-Pousa, Secundino,
Gascón-Bayarri, Jordi,
Garre-Olmo, Josep
Background and Objective: Anosognosia is a disorder that affects the clinical presentation of Alzheimer’s disease (AD), increasing in frequency with the evolution of AD. The objective was to determine the prevalence of anosognosia and analyze the associated factors and predictors.; Patients and Method: Multicenter transversal and observational study of 345 AD patients. Anosognosia was assessed […]
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer’s disease (AD).; Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory […]
Genetic variation in galectin-3 gene associates with cognitive function at old age
Trompet, Stella,
Jukema, Wouter,
Mooijaart, Simon P.,
Ford, Ian,
Stott, David J.,
Westendorp, Rudi G.J.,
de Craen, Anton J.M.
Inflammation plays an important role in the development of cognitive decline and dementia in old age. Galectin-3 is known for its role in acute and chronic inflammation. We assessed whether genetic variation in the LGALS3 gene, encoding for galectin-3, associates with cognitive function in the 5804 participants of the PROspective Study of Pravastatin in the […]
The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study
Trollor, Julian N.,
Smith, Evelyn,
Agars, Emmeline,
Kuan, Stacey A.,
Baune, Bernhard T.,
Campbell, Lesley,
Samaras, Katherine,
Crawford, John,
Lux, Ora,
Kochan, Nicole A.,
Brodaty, Henry,
Sachdev, Perminder
Inflammation may contribute to cognitive decline and dementia. This study examined the cross-sectional relationships between markers of systemic inflammation (C-reactive protein, interleukins-1β, -6, -8, -10, -12, plasminogen activator inhibitor, serum amyloid A, tumour necrosis factor-α and vascular adhesion molecule-1) and cognitive function in 873 non-demented community-dwelling elderly participants aged 70-90 years. Regression analyses were performed […]
Neuroimaging predictors of brain amyloidosis in mild cognitive impairment
Objective: To identify a neuroimaging signature predictive of brain amyloidosis as a screening tool to identify individuals with mild cognitive impairment (MCI) that are most likely to have high levels of brain amyloidosis or to be amyloid-free.; Methods: The prediction model cohort included 62 MCI subjects screened with structural magnetic resonance imaging (MRI) and (11) […]